Peroxisome Proliferator-Activated Receptor γ Is Highly Expressed in Pancreatic Cancer and Is Associated With Shorter Overall Survival Times

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical Cancer Research

• Publication date

  2006-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-06-0834PMID 17085658
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peroxisome proliferator-activated receptor gamma in malignant diseases.

  2006cited by this paper
• Peroxisome proliferator-activated receptor in malignant diseases

  2006cited by this paper
• Activation of Peroxisome Proliferator-Activated Receptor-γ Decreases Pancreatic Cancer Cell Invasion through Modulation of the Plasminogen Activator System

  2006cited by this paper
• A Phase II Study of Weekly Cisplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer: Is This a Strategy Still Worth Pursuing?

  2006cited by this paper
• PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value.

  2005cited by this paper
• PPARγ expression in breast cancer: clinical value and correlation with ERβ

  2005cited by this paper
• Cancer Statistics, 2005

  2005cited by this paper
• Relationship between peroxisome proliferator-activated receptor-gamma expression and differentiation of human esophageal squamous cell carcinoma.

  2005cited by this paper
• The Nonthiazolidinedione Tyrosine-Based Peroxisome Proliferator-Activated Receptor γ Ligand GW7845 Induces Apoptosis and Limits Migration and Invasion of Rat and Human Glioma Cells

  2005cited by this paper
• An overview on biological mechanisms of PPARs.

  2005cited by this paper
• Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia.

  2004cited by this paper
• The localisation and reduction of nuclear staining of PPARgamma and PGC-1 in human breast cancer.

  2004cited by this paper
• PPAR gamma signaling exacerbates mammary gland tumor development.

  2004cited by this paper
• Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays.

  2004cited by this paper
• Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma

  2004cited by this paper
• PPAR signaling exacerbates mammary gland tumor development

  2004cited by this paper
• Pathology of small cell carcinoma of the lung.

  2003cited by this paper
• Expression of PPAR-gamma is correlated with the clinical course of neuroblastoma.

  2003cited by this paper
• Ligands for peroxisome proliferator-activated receptor γ inhibit growth of pancreatic cancers both in vitro and in vivo

  2003cited by this paper
• Selective activation of PPARγ inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator

  2003cited by this paper
• Coactivator PRIP, the Peroxisome Proliferator-activated Receptor-interacting Protein, Is a Modulator of Placental, Cardiac, Hepatic, and Embryonic Development*

  2003cited by this paper
• Expression of peroxisome‐proliferator activated receptor‐gamma (PPARγ) and the PPARγ co‐activator, PGC‐1, in human breast cancer correlates with clinical outcomes

  2003cited by this paper
• Selective activation of PPARgamma inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator.

  2003cited by this paper
• Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study

  2003cited by this paper
• New perspectives in the management of pancreas cancer.

  2003cited by this paper
• Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma.

  2002cited by this paper
• Activation of Peroxisome Proliferator-Activated Receptor Gamma Inhibits the Growth of Human Pancreatic Cancer

  2002cited by this paper
• Expression of PAX8-PPARγ1 Rearrangements in Both Follicular Thyroid Carcinomas and Adenomas

  2002cited by this paper
• Expression of peroxisome proliferator‐activated receptor (PPAR) in human prostate cancer

  2002cited by this paper
• Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade.

  2002cited by this paper
• Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas.

  2002cited by this paper
• Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo.

  2001cited by this paper
• Peroxisome proliferator-activated receptor gamma induces pancreatic cancer cell apoptosis.

  2001cited by this paper
• Expression of Peroxisome Proliferator-Activated Receptor γ in Renal Cell Carcinoma and Growth Inhibition by Its Agonists

  2001cited by this paper
• Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis.

  2001cited by this paper
• Peroxisome Proliferator-Activated Receptor γ Induces Pancreatic Cancer Cell Apoptosis

  2001cited by this paper
• Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists.

  2001cited by this paper
• PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells.

  2000cited by this paper
• Presence and inducibility of peroxisomes in a human glioblastoma cell line.

  2000cited by this paper
• Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells.

  2000cited by this paper
• Roles of PPARs in health and disease

  2000cited by this paper
• Expression of peroxisome proliferator‐activated receptors (PPARS) in human astrocytic cells: PPARγ agonists as inducers of apoptosis

  2000cited by this paper
• Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists

  2000cited by this paper
• Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis.

  2000cited by this paper
• Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.

  2000cited by this paper
• Loss-of-function mutations in PPAR gamma associated with human colon cancer.

  1999cited by this paper
• Loss-of-Function Mutations in PPARγ Associated with Human Colon Cancer

  1999cited by this paper
• An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer

  1999cited by this paper
• Expression of Peroxisome Proferator-Activated Receptor γ (PPARγ) in Human Transitional Bladder Cancer and its Role in Inducing Cell Death

  1999cited by this paper
• Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death.

  1999cited by this paper
• Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids.

  1999cited by this paper
• Activators of the nuclear receptor PPARgamma enhance colon polyp formation.

  1998cited by this paper
• Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice.

  1998cited by this paper
• Terminal differentiation of human breast cancer through PPAR gamma.

  1998cited by this paper
• Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice

  1998cited by this paper
• Activators of the nuclear receptor PPARγ enhance colon polyp formation

  1998cited by this paper
• Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.

  1997cited by this paper
• Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator–Activated Receptors and Liver X Receptor-α in Humans: No Alteration in Adipose Tissue of Obese and NIDDM Patients

  1997cited by this paper
• Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology.

  1996cited by this paper
• Differential expression and activation of a family of murine peroxisome proliferator-activated receptors.

  1994cited by this paper
• Diverse peroxisome proliferator-activated receptors bind to the peroxisome proliferator-responsive elements of the rat hydratase/dehydrogenase and fatty acyl-CoA oxidase genes but differentially induce expression.

  1993cited by this paper

• A New Era for PPARγ: Covalent Ligands and Therapeutic Applications.

  2025cites this paper
• Prognostic Model Construction of Disulfidptosis-Related Genes and Targeted Anticancer Drug Research in Pancreatic Cancer

  2024cites this paper
• The Emergence of TRP Channels Interactome as a Potential Therapeutic Target in Pancreatic Ductal Adenocarcinoma

  2023cites this paper
• Dual PPARγ/ɑ Agonist Oroxyloside Suppresses Cell Cycle Progression by Glycolipid Metabolism Switch-Mediated Increase of Reactive Oxygen Species Levels.

  2021cites this paper
• ERRα inhibitor acts as a potential agonist of PPARγ to induce cell apoptosis and inhibit cell proliferation in endometrial cancer

  2020cites this paper
• Several Biomolecular Parameters as Prognostic, Therapeutic and Preventive Factors of Nasopharyngeal Carcinoma

  2020cites this paper
• Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications.

  2019cites this paper
• The Anticancer Potential of Peroxisome Proliferator‐Activated Receptor Antagonists

  2018cites this paper
• Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy

  2018cites this paper
• Impact of Concurrent Medication Use on Pancreatic Cancer Survival—SEER-Medicare Analysis

  2017cites this paper
• Regulation of the kRAS Promoter in Pancreatic Cancer by Proteins and Small Molecules

  2017cites this paper
• An insight of consequences of body weight on altered expression of nuclear receptors and interrelation of cyclooxygenase-2 in human colorectal cancers

  2017cites this paper
• Human profilin 1 is a negative regulator of CTL mediated cell‐killing and migration

  2017cites this paper
• Fatty acid activated PPARγ promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter

  2016cites this paper
• Masitinib plus gemcitabine for personalized treatment of PDAC patients with overexpression of ACOX1

  2016cites this paper
• Clinical relevance of peroxisome proliferator-activated receptor-gamma expression in myxoid liposarcoma

  2016cites this paper
• Inhibition of Prostaglandin Reductase 2, a Putative Oncogene Overexpressed in Human Pancreatic Adenocarcinoma, Induces Oxidative Stress-Mediated Cell Death Involving xCT and CTH Gene Expressions through 15-Keto-PGE2

  2016cites this paper
• Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer.

  2016cites this paper
• Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas

  2015influential citation
• Peroxisome proliferator-activated receptor-γ inhibits pancreatic cancer cell invasion and metastasis via regulating MMP-2 expression through PTEN.

  2015cites this paper
• A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer

  2015cites this paper
• Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor γ overexpression in human pancreatic carcinoma.

  2015cites this paper
• Thiazolidine-2,4-diones as multi-targeted scaffold in medicinal chemistry: Potential anticancer agents.

  2014cites this paper
• Emerging role of the β-catenin-PPARγ axis in the pathogenesis of colorectal cancer.

  2014cites this paper
• Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): at the cross-road of pancreatic cancer cell proliferation.

  2014cites this paper
• Nuclear receptors in pancreatic tumor cells.

  2014cites this paper
• T0070907, a PPAR γ Inhibitor, Induced G2/M Arrest Enhances the Effect of Radiation in Human Cervical Cancer Cells Through Mitotic Catastrophe

  2014cites this paper
• Identification of a C-FABP-PPARγ-VEGF axis promoting tumorigenicity in prostate cancer cells

  2014cites this paper
• Nuclear receptors and pathogenesis of pancreatic cancer.

  2014cites this paper
• Combined treatment with PPAR-γ agonists in pancreatic cancer: a glimmer of hope for cancer therapy?

  2013cites this paper
• Tissue Distribution and Versatile Functions of PPARs

  2013cites this paper
• Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells

  2013cites this paper
• Metabolic Derangements in Pancreatic Cancer

  2013cites this paper
• Correlations among PPARγ, DNMT1, and DNMT3B Expression Levels and Pancreatic Cancer

  2012cites this paper
• PPARs Signaling and Cancer in the Gastrointestinal System

  2012cites this paper
• Google Goes Cancer: Improving Outcome Prediction for Cancer Patients by Network-Based Ranking of Marker Genes

  2012cites this paper
• PPARG Epigenetic Deregulation and Its Role in Colorectal Tumorigenesis

  2012cites this paper
• Peroxisome proliferator‐activated receptors and cancer: challenges and opportunities

  2011cites this paper
• The complexities of obesity and diabetes with the development and progression of pancreatic cancer.

  2011cites this paper
• Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis

  2011cites this paper
• Body Mass Index and Obesity- and Diabetes-Associated Genotypes and Risk for Pancreatic Cancer

  2011cites this paper
• Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentation of cholangiocarcinoma

  2011cites this paper
• Peroxisome proliferator-activated receptor-γ in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival

  2011cites this paper
• Imaging , Diagnosis , Prognosis Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma : A Systematic Review and Meta-analysis

  2011cites this paper
• PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells.

  2011cites this paper
• The complexities of obesity , diabetes , and the development and progression of pancreatic cancer

  2011cites this paper
• Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer

  2011cites this paper
• Genomic Evaluation of Pancreatic Neoplasms

  2010cites this paper
• The use of Cox-2 and PPARγ signaling in anti-cancer therapies.

  2010cites this paper
• Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus–transgenic mice by peroxisome proliferator‐activated receptor γ–independent regulation of nucleophosmin

  2010cites this paper
• Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition.

  2009cites this paper
• PPARγ/PGC-1α Pathway in E-Cadherin Expression and Motility of HepG2 Cells

  2009cites this paper
• Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival.

  2009cites this paper
• PPAR(gamma)/PGC-1(alpha) pathway in E-cadherin expression and motility of HepG2 cells.

  2009cites this paper
• Prognostic significance of AGR2 in pancreatic ductal adenocarcinoma.

  2009cites this paper
• CHAPTER 76 – Pancreatic Neoplasms

  2009cites this paper
• Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival.

  2009cites this paper
• Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?

  2009cites this paper
• Obesity and Breast Cancer: The Roles of Peroxisome Proliferator-Activated Receptor-γ and Plasminogen Activator Inhibitor-1

  2009cites this paper
• Molecular alterations in exocrine neoplasms of the pancreas.

  2009cites this paper
• Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling

  2008cites this paper
• The Role of PPAR-γ and Its Interaction with COX-2 in Pancreatic Cancer

  2008cites this paper
• Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.

  2008cites this paper
• Neoexpression von Netrin-1, UNC5H3, DCC und Neogenin in duktalen Adenokarzinomen des Pankreas. Mögliche prognostische Marker mit therapeutischer Relevanz?

  2008cites this paper
• PPARs Mediate Lipid Signaling in Inflammation and Cancer

  2008cites this paper
• Inhibition of peroxisome proliferator‐activated receptor γ activity suppresses pancreatic cancer cell motility

  2008cites this paper
• To Live or to Die: Prosurvival Activity of PPARγ in Cancers

  2008cites this paper
• ReviewArticle PPARs Mediate Lipid Signaling in Inflammation and Cancer

  2008cites this paper
• The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers

  2007cites this paper
• Fatty acid activated PPAR promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter.

  year unknowncites this paper